Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 7/20 | 0.32 |
| ▸ | RXRB | P28702 | 6/20 | 0.32 |
| ▸ | RXRG | P48443 | 6/20 | 0.32 |
| ▸ | APEX1 | P27695 | 1/20 | 0.31 |
| ▸ | RARA | P10276 | 3/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17280430 | 0.90 | HSD17B10 (0.30) | HSD17B10 | |
| SCHEMBL17280443 | 0.88 | NPC1 (0.31) | — | |
| SCHEMBL130725 | 0.88 | RXRA (0.33) | RXRARXRBRXRGAPEX1RARA | |
| SCHEMBL29879856 | 0.88 | RXRA (0.33) | RXRARXRBRXRGAPEX1RARA | |
| SCHEMBL17277948 | 0.88 | CA1 (0.32) | HSD17B10 | |
| SCHEMBL17280432 | 0.84 | — | — | |
| SCHEMBL17285537 | 0.83 | TNFRSF1A (0.33) | RXRARXRBRXRGRARA | |
| SCHEMBL15685032 | 0.81 | — | — | |
| SCHEMBL19248350 | 0.81 | APEX1 (0.35) | APEX1 | |
| SCHEMBL17280440 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9221850-B2 | Monophosphite ligands having a tert-butyloxycarbonyl group | EVONIK INDUSTRIES AG (DE) | 2015-12-29 | — | — | US | disclosed |
| US-20150336988-A1 | NOVEL MONOPHOSPHITE LIGANDS HAVING A TERT-BUTYLOXYCARBONYL GROUP | EVONIK INDUSTRIES AG (DE) | 2015-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336988-A1 | NOVEL MONOPHOSPHITE LIGANDS HAVING A TERT-BUTYLOXYCARBONYL GROUP | TERF2, NUDT1, TERF2IP | RXRA 2844/4885RXRB 2707/4885RXRG 2078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.